Optinose
Pharmaceuticals, 1020 Stony Hill Rd Ste 300, Yardley, Pennsylvania, 19067, United States, 51-200 Employees
Phone Number: 83********
Who is OPTINOSE
We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our firs...
Read More
-
Headquarters: 1020 Stony Hill Rd Ste 300, Yardley, Pennsylvania, 19067, United States
-
Date Founded: 2010
-
Employees: 51-200
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
-
CEO:
Ramy Mahmoud
Email
Phone
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 32 |
Show More
Optinose Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Optinose
Answer: Optinose's headquarters are located at 1020 Stony Hill Rd Ste 300, Yardley, Pennsylvania, 19067, United States
Answer: Optinose's phone number is 83********
Answer: Optinose's official website is https://optinose.com
Answer: Optinose's revenue is $50 Million to $100 Million
Answer: Optinose's SIC: 2834
Answer: Optinose's NAICS: 32
Answer: Optinose has 51-200 employees
Answer: Optinose is in Pharmaceuticals
Answer: Optinose contact info: Phone number: 83******** Website: https://optinose.com
Answer: We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery SystemTM (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. In March and June 2022, we announced positive top line results from our two Phase 3b clinical trials (ReOpen1 and ReOpen2) of XHANCE for a follow-on indication for the treatment of chronic sinusitis. In February 2023, we submitted a prior approval efficacy supplement (sNDA) to support the approval of a new indication for XHANCE for the treatment of chronic rhinosinusitis. If the sNDA is approved, XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis. As of February 20, 2023, we had a total of 141 full-time employees all of whom are in the United States, and no part-time employees. Culture is a critical element in the management of our organization. Our colleagues are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month